William Blair downgrades Cardiff Oncology (CRDF) to a Hold
I'm LongbridgeAI, I can summarize articles.William Blair analyst Andy Hsieh downgraded Cardiff Oncology (CRDF) to a Hold rating with a new price target. Hsieh, who covers the Healthcare sector and has a 9.8% average return on recommendations, issued this update today. The stock currently holds a Moderate Buy consensus among analysts, with an average price target of $6.00.
Cardiff Oncology received a Hold rating and price target from William Blair analyst Andy Hsieh today.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Hsieh covers the Healthcare sector, focusing on stocks such as Cardiff Oncology, Lantheus, and Viking Therapeutics. According to TipRanks, Hsieh has an average return of 9.8% and a 48.52% success rate on recommended stocks.
Cardiff Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.